Blood Podcast

In this week's episode, we'll learn about how TET2 is often mutated in myeloid malignancies and clonal hematopoiesis. In new work, expansion of Tet2-mutant HSPCs was dependent on Ncoa4, the cargo receptor mediating ferritinophagy. We’ll iron out the implications. After that: a double-oh-seven license to kill in T-cell leukemia/lymphoma. WU-CART-007 is an off-the-shelf CAR T product with manageable safety and encouraging efficacy. With further work, it could become a new option for patients in urgent need of therapy. Finally: a comprehensive genetic study of classical Hodgkin lymphoma using circulating tumor DNA. This new research provides novel and complex insights on genetic subtypes, prognostic biomarkers, neoantigens in the disease environment, and more.Featured Articles:An in vivo barcoded CRISPR-Cas9 screen identifies Ncoa4-mediated ferritinophagy as a dependence in Tet2-deficient hematopoiesisPhase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignanciesA comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA

In this week's episode we'll learn about targeting NPM1 in acute myeloid leukemia. Researchers report the first clinical evidence of a menin inhibitor inducing complete remissions in AML with a NPM1 mutation. This validates NPM1 as a new therapeutic target in AML, alongside FLT3, IDH1/2, and KMT2A. Also on the podcast: targeting CD137 to prevent graft-versus-host disease. In nonhuman primates, a single dose of a CD137 antibody-drug conjugate provided long-term protection, with one important caveat: the potential for viral reactivation.Featured Articles: Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 studyA single dose of a CD137 antibody–drug conjugate protects rhesus macaque allogeneic HCT recipients against acute GVHD

Blood Editor, Dr. Thomas Coates interviews Dr. Emanuele Angelucci on his paper, "How I manage iron overload in the hematopoietic cell transplantation setting" which is featured in Blood's "How I Treat Series on Iron Overload in Hematologic Disorders". See the full How I Treat series in volume 145 issue 4 of Blood. 

In this week's episode we'll learn about how by combining PET response with circulating tumor DNA, or  ctDNA, in newly treated patients with follicular lymphoma, investigators identify those patients likely to progress within 24 months of initial treatment, also known as POD24. After that: Immune hotspots in aplastic anemia. These newly identified hotspots potentially represent sites in the bone marrow where the active immune response takes place, driving the destruction of hematopoietic stem and progenitor cells. Finally, allogeneic transplantation for Hodgkin lymphoma in the checkpoint inhibitor era. In a large, retrospective study, patients with prior checkpoint inhibitor exposure had remarkable outcomes, particularly when post-transplant cyclophosphamide was used.Featured Articles: Combined PET and ctDNA response as predictors of POD24 for follicular lymphoma after first-line induction treatmentImaging Mass Cytometry Reveals the Order of Events in the Pathogenesis of Immune-Mediated Aplastic AnemiaOutcomes of Allogeneic HCT in Hodgkin Lymphoma in the Era of Checkpoint Inhibitors: A Joint CIBMTR and EBMT Analysis

Explore the impact of exogenous CD19 stimulation on CAR T-cell persistence in treating B-cell acute lymphoblastic leukemia. Discover innovative rapid immune assays that enhance the diagnosis of heparin-induced thrombocytopenia, making recognition quicker and more reliable. Delve into new survival prediction models for chronic myelomonocytic leukemia, which integrate clinical data and genetic factors to refine patient selection for stem cell transplants, ultimately improving outcomes.

Join Dr. Selina Luger and a panel of AML experts: Dr. Andrew Wei, a researcher on azacitidine and venetoclax at the Peter MacCallum Cancer Centre; Dr. Gail Roboz, who specializes in maintenance therapy at Weill Cornell Medicine; Dr. Eunice Wang, who addresses secondary AML challenges at Roswell Park; and Dr. Courtney DiNardo, focused on targeted therapies at MD Anderson. They discuss groundbreaking outpatient therapies, the complexities of maintenance strategies, and advancements in differentiating agents that may improve patient outcomes.

In this week's episode, we’ll learn more about the effects of daratumumab maintenance on minimal residual disease in patients with newly diagnosed, transplant-eligible multiple myeloma; the role of neutrophils in the pathophysiology of myeloproliferative neoplasms; and a genome-wide association study that identified novel genetic loci associated with the risk of heavy menstrual bleeding.Featured ArticlesDaratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease resultsDefective neutrophil clearance in JAK2^V617F myeloproliferative neoplasms drives myelofibrosis via immune checkpoint CD24Genome-wide meta-analysis of heavy menstrual bleeding reveals 36 risk loci

Discover groundbreaking research on hematopoietic stem cells that enhances transplant success. Learn how ruxolitinib is transforming treatment for refractory macrophage activation syndrome. Explore fascinating trials that assess magrolimab’s role in acute myeloid leukemia, revealing unexpected challenges in efficacy and safety. This episode dives into innovative therapies and the pivotal role of neutrophils in improving patient outcomes, showcasing the latest advancements in transplant biology and hematological treatments.

Discover a new JAK inhibitor showing promise in reducing complications from CAR T-cell therapy, with a focus on preventing cytokine release syndrome and neurotoxicity. Dive into a fascinating study revealing how interactions between a popular vaccine and platelets might lead to post-vaccination arterial thrombosis. Lastly, learn about the alarming phenomenon of lineage switch in leukemia relapses, which poses serious challenges after immunotherapy, underscoring the urgent need for innovative detection and treatment methods.

Discover the latest in hematological treatments, including the promising combination of ruxolitinib and dexamethasone for hemophagocytic lymphohistiocytosis. Delve into innovative lysine-specific demethylase-1 inhibitors that show potential for treating sickle cell disease. The discussion also covers the complexities of low von Willebrand factor levels, highlighting clinical implications and the necessity for personalized treatment approaches.